Learning Objectives

  • Analyze factors of ‘set and setting’ as they relate to a) physical features of a dosing environment; b) therapist gender identity; c) the role of race, culture, and ethnicity; and d) early sexual, physical, and/or emotional abuse histories.

  • List current evidence-based practices for use of therapeutic ketamine to optimize safe, effective, and ethical ketamine administration and dosing.

  • Prepare a plan to help patients navigate a range of treatment outcomes, including those related to disappointment and/or sudden wellness.

Instructor(s)

Lead Trainer

Casey Paleos, MD

Casey Paleos, MD is a psychiatrist and researcher with over a decade of experience in the use of psychedelic medicines for the treatment of mental illness, dating back to his work, while still in residency training, as a study therapist in the landmark Psilocybin Cancer Anxiety Study at NYU, where Dr. Guss was one of his mentors. Since then, Dr. Paleos was Co-Principal Investigator in the NYU-Bellevue Ketamine for Depression Study and has been treating patients in his private practice with both ketamine infusion therapy and ketamine-assisted psychotherapy since 2016. Presently, he is a study therapist and Principal Investigator, alongside Dr. Gorman, in the MAPS-sponsored MDMA-Assisted Psychotherapy for PTSD Phase 3 Clinical Trial, serves as Scientific Director at Mindbloom, Inc., and is a co-founder of Nautilus Sanctuary, a non-profit psychedelic research and clinical institution based in New York City.

Lead Trainer

Jeffrey Guss, MD

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, a collaborator with Yale University’s study on psilocybin-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS study on treatment of Post Traumatic Stress Disorder with MDMA-Assisted Psychotherapy. Jeff is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research in The Journal of Psychedelic Studies. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.

Instructor(s)

Lead Trainer

Ingmar Gorman, PhD

Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.

Lead Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Continuing Education Information

This course provides 3.5 hours of APA CE and NYSED CE for Psychologists, Social Workers, and LMHCs.

  • Fluence International, Inc. is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0674

  • Fluence International, Inc. is recognized by the New York State Education Department's State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0232.

  • Fluence International, Inc. is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0167.

  • Fluence International, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists.

  • Fluence maintains responsibility for th is program and its content. For questions about CE for this program contact Selah Drain, Selah@fluencetraining.com.